BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2017
View Archived Issues
AG-348 well tolerated in updated data from phase II DRIVE PK study
Read More
WHSC1 revealed as a promising therapeutic target for ALL
Read More
Characterization of next-generation anti-CD19 half-life extended BiTE antibody
Read More
TP-0903 demonstrates promising in vitro and in vivo activity
Read More
NuCana BioMed patents adenosine derivatives for cancer
Read More
RedHill Biopharma begins phase IIa study of Yeliva in cholangiocarcinoma
Read More
FGFR inhibitors reported in Shanghai Allist Pharmaceutical patent
Read More
Enlibrium describes biguanide derivatives
Read More
Phase II study of anabasum in SLE begins
Read More
Arrowhead Pharmaceuticals seeks approval for phase I/II study of HBV drug
Read More
FDA issues complete response letter for Agile's Twirla
Read More
Mallinckrodt to acquire Sucampo Pharmaceuticals
Read More
FDA grants fast track designation for VAL-083 in recurrent glioblastoma
Read More
FDA updates Tasigna label to include information on stopping therapy in certain CML patients
Read More
Ono submits supplemental application for Opdivo in Japan
Read More
Poxel and Sumitomo Dainippon Pharma initiate phase III program for imeglimin
Read More
Arno Therapeutics sells remaining assets
Read More
Soliris approved in Japan for the treatment of patients with generalized myasthenia gravis
Read More
CG-806 receives orphan drug designation from FDA for treatment of AML
Read More
FDA grants fast track designation to cannabidiol oral solution for Prader-Willi syndrome
Read More
Agios submits NDA for ivosidenib to treat relapsed/refractory AML with an IDH1 mutation
Read More
Portola Pharmaceuticals provides update on BLA for AndexXa
Read More
Summit acquires Discuva and obtains innovative antibiotic discovery and development platform
Read More